Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LDLR | P01130 | 1/20 | 0.43 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16340027 | 0.99 | ITGB3 (0.49) | ITGB3ITGA2BSLC2A1NPC1RAB9A | |
| SCHEMBL16339315 | 0.88 | MAPT (0.43) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL16339479 | 0.87 | MEN1 (0.41) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL16339901 | 0.87 | MAPT (0.43) | ITGB3ITGA2BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16339631 | 0.86 | HDAC2 (0.51) | RAB9AL3MBTL1HDAC3 | |
| SCHEMBL24032909 | 0.86 | MAPK7 (0.44) | MAPTHTTCDK4CCND3HDAC3 | |
| Hydrochloric Acid SCHEMBL17765374 | 0.85 | HDAC2 (0.50) | RAB9AL3MBTL1HDAC3 | |
| SCHEMBL17765375 | 0.84 | HDAC3 (0.41) | SLC2A1MAPTLDLRPCSK9CDK4 | |
| Hydrochloric Acid SCHEMBL25418691 | 0.82 | HDAC3 (0.47) | CDK4USP25F10HDAC3 | |
| SCHEMBL16339293 | 0.82 | MAPT (0.54) | SLC2A1SMN1; SMN2MAPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021007378-A1 | COMPOUNDS FOR USE IN TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | WO | claimed |
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | claimed |
| EP-3013345-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2017-11-22 | — | — | EP | claimed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | claimed |
| EP-3013345-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2016-05-04 | — | — | EP | claimed |
| WO-2014209841-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-31 | — | — | WO | claimed |
| WO-2021007378-A1 | COMPOUNDS FOR USE IN TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| WO-2021007378-A1 | COMPOUNDS FOR USE IN TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | disclosed |
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | disclosed |
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | disclosed |
| EP-3013345-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2017-11-22 | — | — | EP | disclosed |
| EP-3013345-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3013345-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014209841-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014209841-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, PYGM | ITGB3 2241/4885ITGA2B 1260/4885SLC2A1 2840/4885 |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, PYGM | ITGB3 2241/4885ITGA2B 1260/4885SLC2A1 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.